TERT promoter mutations in thyroid cancer

Rengyun Liu; Mingzhao Xing

doi:10.1530/ERC-15-0533

TERT promoter mutations in thyroid cancer

Rengyun Liu and
Mingzhao Xing⇑

Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes and Metabolism, The Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA

Correspondence should be addressed to M Xing; Email: mxing1{at}jhmi.edu

View larger version:
- In this window
- In a new window
- Download as PowerPoint Slide
Figure 1
Meta-analysis of the association of TERT promoter mutations with extrathyroidal invasion (A) and vascular invasion (B) of thyroid cancer. The between-study heterogeneity was tested by a χ²-based Q-test and quantified by the I² metric, which ranged from 0 to 100% and was considered low for I² <25%, modest for 25–50%, and large for >50% (Higgins et al. 2003). The combined OR was calculated by the fixed-effects model (the Mantel–Haenszel method) when between-study heterogeneity was absent (Mantel & Haenszel 1959); otherwise the random-effects model (the Dersimonian and Laird method) was used (Dersimonian & Laird 1986). The circles and horizontal lines correspond to the study-specific OR and 95% CI respectively. The combined ORs and their 95% CIs are indicated by the diamonds. PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; PDTC, poorly differentiated thyroid cancer; ATC, anaplastic thyroid cancer. OR, odds ratio.
View larger version:
- In this window
- In a new window
- Download as PowerPoint Slide
Figure 2
Meta-analysis of the association of TERT promoter mutations with thyroid cancer distant metastasis (A), tumor stage III/IV (B), tumor recurrence (C) and patients mortality (D). The between-study heterogeneity and combined OR were calculated as described in the legend to Fig. 1. The circles and horizontal lines correspond to the study-specific OR and 95% CI. The combined ORs and their 95% CIs are indicated by the diamonds. PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; PDTC, poorly differentiated thyroid cancer; ATC, anaplastic thyroid cancer. OR, odds ratio.
View larger version:
- In this window
- In a new window
- Download as PowerPoint Slide
Figure 3
Meta-analysis of the association between BRAF V600E and TERT promoter mutations in thyroid cancer. The between-study heterogeneity and combined OR were calculated as described in Fig. 1. The circles and horizontal lines correspond to the study-specific OR and 95% CI. The combined ORs and their 95% CIs are indicated by the diamonds. PTC, papillary thyroid cancer; PDTC, poorly differentiated thyroid cancer; ATC, anaplastic thyroid cancer. OR, odds ratio.